Antibodies News and Research

RSS

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

COVID Moonshot receives key funding to accelerate drug discovery efforts

The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from Wellcome, on behalf of the Covid-19 Therapeutics Accelerator.

28 Sep 2021

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.

27 Sep 2021

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

Researchers in Japan have conducted a study showing that the vaccine developed by Pfizer-BioNTech to protect against coronavirus disease 2019 (COVID-19) seems to be adequately effective against the B.1.621 (mu) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

27 Sep 2021

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

A version of SARS-CoV-2, the virus that causes COVID-19 disease, has been successfully modified to glow brightly in cells and animal tissues, providing a real-time way to track the spread and intensity of viral infection as it happens in animal models, researchers at Texas Biomedical Research Institute report in the journal The Proceedings of the National Academy of Sciences.

27 Sep 2021

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

A new study discusses the utility of a third booster dose in patients with myelofibrosis.

27 Sep 2021

Monoclonal antibodies may reduce hospital stay, but not mortality in COVID-19

A new study explores the real-world efficacy of monoclonal antibodies against COVID-19 in averting severe disease.

27 Sep 2021

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new study discusses the isolation of two variants of concern (VOCs) from an immunocompromised COVID-19 patient.

27 Sep 2021

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

New research discusses the development of soluble prefusion-stabilized spike trimers (CoV2 preS dTM) comprising adjuvant AS03.

27 Sep 2021

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

A new study describes a new variant that possesses a novel combination of various concerning mutations at the spike region.

27 Sep 2021

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

A new review article investigates the clinical and viral characteristics, pathogenesis, as well as human genetic basis associated with COVID-19.

27 Sep 2021

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

A team from the National Institute for Infectious Diseases “L. Spallanzani” (INMI) has recently reported their study on 94 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections (47.9% symptomatic, 52.1% asymptomatic) that occurred after the first or second vaccine dose against SARS-CoV-2 in the Lazio region (Central Italy).

27 Sep 2021

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Despite the advent of numerous vaccines and the discovery of passive monoclonal antibodies for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there remains an urgent need for definitive therapies for coronavirus disease-2019 (COVID-19) patients.

27 Sep 2021

SARS-CoV-2 infection less severe in children and youth during first part of the pandemic

New research has found that children and youth may be at low risk of severe acute COVID-19, according to a study conducted during the first half of the pandemic and published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.210053.

27 Sep 2021

mRNA COVID vaccines prove effective in the elderly

Coronavirus disease 2019 (COVID-19) proved extremely difficult to control once it entered a country – while there were a few success stories such as New Zealand, most countries ended up resorting to lengthy and economically painful lockdowns, among other restriction measures.

27 Sep 2021

WHO urges to address the high price and limited production of antibody combination for COVID-19

The World Health Organization (WHO) welcomes the addition of another therapeutic to the world's arsenal against COVID-19, but urges producing companies and governments to address the high price and limited production of the Regeneron antibody combination and ensure safe and appropriate handling of the medicine.

27 Sep 2021

Study shows prior COVID-19 and vaccination protects elderly against variants

In order to qualify the risk posed to the elderly, researchers from MUSE University in France began to investigate data from nursing homes that had faced outbreaks from variants of concern. Their work can be found on the medRxiv* preprint server while awaiting peer review.

27 Sep 2021

COVID-19 vaccine effectiveness barely affected by Delta variant, research suggests

Has the Delta (B.1.617.2) variant reduced vaccine effectiveness? If you ask Ian Foster of Argonne National Laboratory and colleagues, the answer is not really. New research published in the preprint medRxiv* server suggests vaccines approved in the United States are stable and well-performing.

27 Sep 2021

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Japanese scientists created "elite" antibodies that defeat various coronavirus variants even at an extremely low dose through a new method that accelerated the months-long process of finding such extraordinary antibody candidates to just ten days.

27 Sep 2021

Study reveals surfaces of SARS-CoV-2 spike most resistant to antibody escape

A team of international scientists has formed a consortium to map the epitope landscape of a range of therapeutic monoclonal antibodies on the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the scientists characterized the neutralization potency of these antibodies and have investigated how emerging viral variants with spike mutations can impact antibody-mediated neutralization. They have recently published the consortium findings in the journal Science.

27 Sep 2021

Antibodies News and Research

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

COVID Moonshot receives key funding to accelerate drug discovery efforts

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

Monoclonal antibodies may reduce hospital stay, but not mortality in COVID-19

Chronic COVID-19 and divergent variants of SARS-CoV-2

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

SARS-CoV-2 infection less severe in children and youth during first part of the pandemic

mRNA COVID vaccines prove effective in the elderly

WHO urges to address the high price and limited production of antibody combination for COVID-19

Study shows prior COVID-19 and vaccination protects elderly against variants

COVID-19 vaccine effectiveness barely affected by Delta variant, research suggests

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Study reveals surfaces of SARS-CoV-2 spike most resistant to antibody escape

Immunology eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News